92 related articles for article (PubMed ID: 11516101)
1. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting.
Varella-Garcia M; Hogan CJ; Odom LF; Murata-Collins JL; Ai H; Chen L; Richkind K; Paskulin G; Andreeff M; Brizard A; McGavran L; Gemmill RM; Berger R; Drabkin HA
Leukemia; 2001 Sep; 15(9):1408-14. PubMed ID: 11516101
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evaluation of probes to detect t(8;21) AML minimal residual disease by fluorescence in situ hybridization.
Paskulin GA; Philips G; Morgan R; Sandberg A; Richkind K; Borovik C; McGavran L; Rabinovich N; Dietz-Band J; Erickson P; Drabkin H; Varella-Garcia M
Genes Chromosomes Cancer; 1998 Feb; 21(2):144-51. PubMed ID: 9491326
[TBL] [Abstract][Full Text] [Related]
3. Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission.
Feuring-Buske M; Haase D; Buske C; Hiddemann W; Wörmann B
Leukemia; 1999 Mar; 13(3):386-92. PubMed ID: 10086729
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J;
Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish.
White DL; Hutchins CJ; Turczynowicz S; Suttle J; Haylock DN; Hughes TP; Juttner CA; To LB
Pathology; 1997 Aug; 29(3):289-93. PubMed ID: 9271020
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission.
Engel H; Goodacre A; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Andreeff M
Br J Haematol; 1997 Oct; 99(1):64-75. PubMed ID: 9359505
[TBL] [Abstract][Full Text] [Related]
8. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
9. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of minimal residual disease in pediatric acute myeloblastic leukemia using metaphase-FISH.
Vettenranta K; Autio K; Hovi L; Knuutila S; Saarinen-Pihkala UM
Leuk Lymphoma; 2002 Jun; 43(6):1261-5. PubMed ID: 12152994
[TBL] [Abstract][Full Text] [Related]
13. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
[TBL] [Abstract][Full Text] [Related]
14. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study.
Mitterbauer M; Mitterbauer-Hohendanner G; Sperr WR; Kalhs P; Greinix HT; Fonatsch C; Haas OA; Jäger U; Mannhalter C; Lechner K
Leuk Lymphoma; 2004 May; 45(5):971-7. PubMed ID: 15291357
[TBL] [Abstract][Full Text] [Related]
15. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
17. Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias.
Brendel C; Mohr B; Schimmelpfennig C; Müller J; Bornhäuser M; Schmidt M; Ritter M; Ehninger G; Neubauer A
Leukemia; 1999 Nov; 13(11):1770-5. PubMed ID: 10557051
[TBL] [Abstract][Full Text] [Related]
18. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications.
Schmidt HH; Strehl S; Thaler D; Strunk D; Sill H; Linkesch W; Jäger U; Sperr W; Greinix HT; König M; Emberger W; Haas OA
Leukemia; 2004 Jun; 18(6):1115-21. PubMed ID: 15085163
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
20. Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia.
Johnston DL; Meshinchi S; Opheim KE; Pallavicini MG; Feusner J; Woods WG; Lange BJ; Radich JP; Bernstein ID
Br J Haematol; 2003 Nov; 123(3):431-5. PubMed ID: 14617001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
